Erectile dysfunction (ED) is highly prevalent in diabetes mellitus. Pathophysiological mechanisms underlying diabetes-associated ED are in large part due to endothelial dysfunction, which functionally refers to the inability of the endothelium to produce vasorelaxing messengers and to maintain vasodilation and vascular homeostasis. The precise mechanisms leading to endothelial dysfunction in the diabetic vasculature, including the penis, are not yet fully understood. Hyperglycemia affects endothelial nitric oxide synthase activity and nitric oxide production/ bioavailability, nitric oxide-independent relaxing factors, oxidative stress, production and/or action of hormones, growth factors and/or cytokines, and generation and activity of opposing vasoconstrictors. Considering recent advances in the field of vascular biology and diabetes, the emphasis in this review is placed on the mechanisms of hyperglycemia-induced endothelial dysfunction in the pathophysiology of diabetes-associated ED.
Introduction
Erectile dysfunction (ED) is the consistent inability to achieve and maintain penile erection sufficient for adequate sexual relations. It is a prevalent condition affecting more than 150 million men worldwide, including 20-30 million men in the USA, and is predicted to double within the next 20 years. 1 ED has psychogenic and organic origins. Up to 80% of ED cases have organic causes. Organic causes of ED include hormonal changes, damage to the penile nerve supply, impaired penile arterial inflow, corporal veno-occlusive dysfunction, or corporal tone derangements.
ED is predominantly a vascular disease. A variety of chronic conditions that involve vascular disorders, such as diabetes, aging, hypercholesterolemia, hypertension, sedentary life style and cigarette smoking are associated with impairment of penile vascular function and characterize vasculogenic ED in men. In fact, ED is considered to be an early manifestation of systemic endothelial dysfunction. 2 ED often precedes and predisposes subsequent atherosclerosis with more severe microvascular and macrovascular alterations.
Based on World Health Organization estimates, 150 million people worldwide are believed to have diabetes, and this figure is expected to double by the year 2025. 3 ED is three times more prevalent in men with types 1 and 2 diabetes than that in nondiabetic men, occurs at an earlier age, and increases with the duration of the disease. It has been estimated that 50-75% of diabetic men have ED of some degree. 4 Studies in diabetic animal models and in human cavernosal tissue from diabetic men have pointed to the multifactorial mechanisms of ED associated with diabetes. Metabolic disorders associated with diabetes include hyperglycemia, excess free fatty acids and insulin resistance. However, a unifying aspect likely associated to some extent with all of these factors is endothelial dysfunction. Endothelial dysfunction primarily reflects the loss of NO biological activity and/or biosynthesis at the endothelial level, but it may also refer to reduced endothelial-dependent vasodilatory response of smooth muscle cells. The pathogenic mechanisms of diabetes-associated endothelial dysfunction in the vasculature, including the penile vascular bed, are incompletely understood. Factors associated with endothelial dysfunction in diabetes include defects in endothelial NO synthase (eNOS) expression and activity; increased oxidative stress; decreased or impaired NO-independent relaxing factors; changes in the production and/or action of hormones, growth factors and cytokines; and increased generation and activity of opposing vasoconstrictors, for example RhoA/Rho-kinase. These mechanisms are not mutually exclusive, and multiple mechanisms may operate simultaneously.
The best-characterized mechanisms associated with endothelial dysfunction in the diabetic vasculature including the penis are caused by hyperglycemia. Elevated free fatty acids, commonly seen in patients with insulin resistance, also induce endothelial dysfunction through the activation of protein kinase C (PKC), increased production of reactive oxygen species (ROS), elevation in triglyceride and LDL, and decrease in HDL levels (reviewed in Creager et al. 5 ). It is possible that the effects of hyperglycemia and insulin resistance on endothelial cells are additive, since defects in both glucose and lipid metabolism produce similar effects with the resultant decrease in endothelial NO availability. 6, 7 While high incidences of metabolic syndrome, insulin resistance and obesity have been demonstrated in men with ED, 8, 9 the molecular mechanisms by which these derangements in association with diabetes produce ED are poorly defined to date. Thus, this review pertains specifically to hyperglycemic effects on endothelial function, with an emphasis on currently known molecular mechanisms within this pathophysiologic context in the diabetic vasculature. We present several mechanisms, which have been described directly in the diabetic penis. However, we also include brief descriptions of mechanisms operating at extragenital sites, surmising their likely relevance for endothelial dysfunction in diabetic ED. For the sake of focus, we have elected to limit a thorough handling of this subject matter to eNOS function, oxidative stress, NO-independent regulatory mechanisms, and RhoA/Rho-kinase signaling. This summary draws extensively from studies using animal models in acknowledgement that much of the current understanding of these areas has resulted mainly from such studies.
Endothelial NO synthase
Decreased relaxation of the cavernosal tissue from diabetic patients with ED and experimental diabetic animals is associated with a lack of NO bioavailability. [10] [11] [12] [13] [14] A reduction in endothelial NO bioavailability can occur by several mechanisms, including decreased expression of eNOS, changes in eNOS activity, and increased degradation of NO, for example by reaction with superoxide. Changes in eNOS activity in response to hyperglycemia may result from decreased availability of cofactors or substrate L-arginine, abnormalities in eNOS phosphorylation, abnormal eNOS regulatory protein interaction, and eNOS uncoupling. Some of these mechanisms may cooperatively reduce NO bioavailability. For example, superoxide anion degrades NO, while it also interacts with eNOS causing the enzyme to produce ROS instead of NO.
eNOS expression
Several studies have shown decreased eNOS expression in the diabetic penis. [12] [13] [14] [15] [16] Consistent with these findings are the reports showing that increased vascular levels of eNOS resulting from adenovirusmediated gene transfer of eNOS to the diabetic rat penis improves penile vascular function and increases erectile response. This effect is mediated by an increase in cGMP formation. 12 Moreover, the combination of eNOS gene therapy and sildenafil results in a synergistic increase in erectile response in diabetic rats, 17 further suggesting the role of impaired NO-mediated responses. However, several studies in the diabetic penis, 11, 18 and an increasing number of studies in nonpenile diabetic vascular beds 19 have shown no changes or increased protein expression of eNOS rather than its decrease, despite diminished NO production. These findings question the notion of decreased expression of eNOS in endothelial dysfunction in diabetes. The signaling mechanisms leading to increased expression of eNOS in diabetic vascular tissues are largely unknown, but they may be due to eNOS uncoupling. In response to oxidative stress, eNOS uncoupling results in upregulated enzyme, which then produces superoxide anion instead of NO. The upregulation of eNOS may represent a compensatory mechanism to increase NO production. 19 Thus, ROS may contribute to the upregulation of eNOS expression seen in diabetes and other types of vascular pathophysiology.
eNOS activity eNOS substrate and cofactors. Reduced content of the eNOS substrate L-arginine may decrease eNOS activity in the diabetic penis. Oral administration of L-arginine to diabetic rabbits and rats increases endothelium-dependent and neurogenic relaxation of cavernosal tissue by improving NO biosynthesis. 20, 21 Decreased L-arginine may be due to competitive interaction with asymmetric dimethylarginine, an endogenous NOS inhibitor, possibly due to its increased levels in association with ROS production. 22 Recent in vitro studies proposed that oxidized LDL in particular is able to decrease local endothelial L-arginine uptake, ultimately leading to both local depletion of L-arginine and eNOS uncoupling. 23 Reduced bioavailable levels of L-arginine for [24] [25] [26] Inhibition of arginase in the diabetic human penis shifts the availability of L-arginine to NOS and enhances NOS activity and cavernosum smooth muscle relaxation. 25 Inactivation of eNOS cofactor tetrahydrobiopterin (BH 4 ) also reduces eNOS activity. BH 4 stabilizes the active dimeric form of eNOS, facilitates electron transfer from the reductase domain to the oxygenase domain of NOS, increases L-arginine binding, and maintains the heme prosthetic group in its redox active form. 27 Exposure of endothelial cells to high concentrations of glucose leads to disruption of the zinc-thiolate cluster on eNOS (where the BH 4 -binding site is located) and reduces intracellular BH 4 bioavailability; this decreases the abundance of the active dimeric form, while total eNOS expression is retained, mainly in the monomeric form.
28 BH 4 -deficient eNOS, when activated, can still receive electrons from NADPH and donate them one at a time to molecular oxygen instead of L-arginine, resulting in one-electron reduction to form superoxide anion. 28 Acute and chronic supplementation of BH 4 improves endothelial function in endothelial cells, experimental diabetic animal models and diabetic patients. 29, 30 The role of this eNOS cofactor in diabetes-associated ED is, however, not known. eNOS phosphorylation. Hyperglycemia may decrease eNOS activity by impairing eNOS phosphorylation. eNOS in the penis is phosphorylated at Ser-1177, Thr-495, Ser-615 and Ser-633 (human sequence, equivalent to Ser-1179, Thr-497, Ser-617, Ser-635 of bovine eNOS).
18,31-34 eNOS phosphorylation at Ser-1177 increases eNOS catalytic activity about twofold and increases constitutive endothelial NO production by reducing the enzyme's calcium requirement and facilitating electron transfer. 35, 36 The most important physiologic stimulator of eNOS phosphorylation at Ser-1177 is shear stress, a pressure exerted on endothelial cells by blood flow in the vessel at a constant flow rate. It has recently been demonstrated that eNOS phosphorylation at Ser-1177 serves an indispensable role in penile erection. 31 While nNOS initiates penile erection in response to sexual stimuli, phosphatidyl inositol 3-kinase (PI3-K)/Akt/eNOS (Ser-1177) phosphorylation causes calcium-'independent' activation of eNOS in the penis and sustained endothelial NO release, accounting for the achievement and maintenance of full erection. 31, 37 eNOS phosphorylation at Thr-495, which occurs within the calmodulinbinding sequence of eNOS, reduces eNOS catalytic activity by decreasing the binding affinity for calcium/calmodulin. PKC signaling has commonly been accepted to promote eNOS phosphorylation at Thr-495 and dephosphorylation at Ser-1177, reducing the enzyme's activity. 38 Several studies have recently described diabetesrelated changes in eNOS phosphorylation. This has been attributed to increased flux of glucose through the hexosamine pathway and formation of N-acetylglucosamine (O-GlcNAc). In bovine aortic and human coronary endothelial cells, aortas isolated from diabetic animals, and carotid plaques from diabetic patients, basal eNOS activity is inhibited by hyperglycemia through O-linked GlcNAc modification of eNOS, which reciprocally decreases phosphorylation of Ser-1177. 39, 40 Recent studies in diabetes-associated ED using a rat model of type 1 diabetes demonstrated decreased phosphorylation of eNOS in the penis specifically at Ser-1177 in association with decreased erectile capability. 18 These studies not only demonstrate that O-GlcNAc modification of eNOS significantly contributes to ED associated with diabetes, but also provide the first evidence for the physiologic relevance of O-GlcNAc modification of eNOS in the diabetic vascular tissue. The diabetes-related deficit in basal eNOS activity in the penis appears to be due to O-GlcNAc modification of the enzyme at Ser-1177 (but not Thr-495, Ser-615 and Ser-633) and a loss of Akt-mediated phosphorylation of eNOS at Ser-1177. The O-GlcNAc modification of eNOS prevents activation of the enzyme by phosphorylation at Ser-1177 in response to fluid shear stress stimuli and vascular endothelial growth factor (VEGF) signaling in parallel with decreased erectile capability in alloxan-induced diabetic rats. 18 eNOS interactions with heat shock protein 90 and caveolin-1. Heat shock protein (Hsp)90 acts as a major protein activator of eNOS. Hsp90 is associated with eNOS in the resting state, and upon stimulation of endothelial cells with stimuli such as VEGF, estrogen, histamine, and shear stress, the association between the two proteins is increased, concomitant with enhanced NO production. 41 The mechanism of this activation involves calmodulin-dependent release of eNOS from caveolin-1, recruitment of eNOS and Akt to adjacent regions on Hsp90, reduced dephosphorylation of Akt, and increased ability of Akt to phosphorylate Hsp90-bound eNOS, which together facilitate eNOS activation by Ser-1177 phosphorylation. [41] [42] [43] High glucose levels may affect eNOS function by altering its proper interaction with Hsp90. Interestingly, during early stages of high glucose exposure, eNOS activity is increased in human umbilical vein endothelial cells through augmentation of its interaction with Hsp90 and Endothelial dysfunction in diabetic ED B Musicki and AL Burnett recruitment of activated Akt. 44 Preservation of eNOS function and prevention of apoptosis by this mechanism may provide a molecular basis for decreased peripheral resistance and increased blood flow in early diabetes. In later stages of high glucose exposure, the protein interaction between eNOS and Hsp90 and the recruitment of activated Akt are downregulated, leading to dysregulation of eNOS and enhanced apoptosis. 44, 45 In bovine aortic endothelial cells high glucose levels decrease the association of eNOS and Hsp90, while metformin, a drug commonly used for the treatment of type 1 diabetes, increases NO release by increasing eNOS association with Hsp90 in a PI3-K/AMP-activated protein kinase (AMPK)-dependent way. Under the same conditions metformin does not affect the association of eNOS with caveolin-1 or eNOS and Hsp90 expressions. 45 In contrast to the effect of Hsp90 interacting with eNOS, the effect of caveolin-1 binding to eNOS in the caveolae is to inhibit the enzyme's activity partly by occupying the calmodulin-binding site, as well as by interfering with other caveolin-associated receptors that stimulate its activity. 46 Receptor activation or humoral and mechanical stimuli such as estrogen and shear stress induce redistribution of eNOS away from plasma membrane caveolae to internal membrane structures, removing its tonic inhibition that results in eNOS activation. 47 Bovine aortic endothelial cells cultured in a high glucose environment, as well as aortas isolated from nonobese diabetic mice, exhibit increased caveolin-1 expression.
48
Hsp90 and caveolin-1 expression and their interactions with eNOS have been documented in the rat penis (Musicki et al., unpublished observations and references 14, 49, 50 ). The penis of the diabetic rat has been reported to contain decreased expression of caveolin-1 compared to that of the nondiabetic rat.
14 No studies have addressed the effect of high glucose on eNOS interaction with Hsp90 and caveolin-1 in the penis. eNOS uncoupling. eNOS (as well as nNOS and iNOS) can switch from a NO-producing enzyme to a superoxide-producing enzyme, a phenomenon termed eNOS uncoupling. In the uncoupled state, electrons normally flowing from the reductase domain of one subunit to the oxygenase domain of the other subunit are diverted to molecular oxygen rather than to L-arginine. This results in the production of superoxide instead of NO, decreasing the functional activity of eNOS. The mechanism underlying eNOS uncoupling is the subject of intense investigation. Oxidation of the zinc thiolate cluster of eNOS and the cofactor BH 4 , and the decreased availability of the NOS substrate L-arginine, have been proposed to lead to monomerization of eNOS, increased production of ROS, and reduced NO production by the enzyme. 28, 51 Bovine aortic endothelial cells exposed to elevated glucose and diabetic mouse heart and aorta have disrupted zinc-thiolate cluster on eNOS, reduced levels of BH 4 , and increased eNOS monomers. 28, 52 eNOS phosphorylation also affects the degree of eNOS coupling. In bovine aortic endothelial cells peroxynitrite inhibits Akt-dependent, but activates AMPK-dependent, phosphorylation of eNOS at Ser-1177. 53 Accelerated electron flux from the reductase to the oxygenase domain of the enzyme increases the activation status of eNOS, although this results in increased production of superoxide anion instead of NO by the uncoupled enzyme. 53 Dephosphorylation of eNOS at Thr-495 may similarly be associated with the enhanced production of superoxide. 54 These studies demonstrate that eNOS uncoupling does not necessarily imply decreased eNOS activity; on the contrary, catalytic activity of the enzyme may be increased, but the enzyme is less functional as a source for NO. Increased association of Hsp90 with eNOS has been demonstrated to 'recouple' eNOS activity (increase NO but decrease eNOS-derived superoxide anion) both in vitro and in animal studies. 55 Thus, eNOS uncoupling refers to both the impaired NO-producing activity of the enzyme as well as its increased capacity to produce superoxide anion.
eNOS uncoupling and reduced abundance of the active dimeric form of eNOS has been documented in the penis of aged rats compared to the young-adult rat penis (Musicki et al., unpublished observations). However, no studies have evaluated whether eNOS uncoupling contributes to diabetesassociated ED.
Oxidative stress
The imbalance between the production and elimination of ROS, a condition known as oxidative stress, has an important role in the development of endothelial dysfunction associated with systemic vascular disorders such as diabetes, aging, hypertension and hypercholesterolemia. Hyperglycemia directly activates oxidative stress, which may affect endothelial function by affecting eNOS function, proinflammatory cytokine activity, growth factor release, and smooth muscle contractility. Potential vascular sources of ROS include NAD(P)H oxidase, uncoupled eNOS, mitochondrial electron transport, xanthine oxidoreductase and cyclooxygenase. 51 Substantial experimental and clinical evidence exists for the involvement of ROS in the development of endothelial dysfunction in the diabetic penis. Penile tissue from diabetic men with ED and streptozotocin-induced diabetic rats contains lower levels of nitrate and nitrite, 56 higher levels of superoxide, 57 and higher levels of malondialdehyde, 56, 58, 59 a product of lipid peroxidation, 60 While the mechanism of p38 MAPK activation and its effect on endothelial dysfunction in diabetic ED is not known, the activity of p38 MAPK may be triggered by hyperglycemia and ROS, as shown in endothelial and smooth muscle cells in nonpenile vascular beds. 61 Endothelial and smooth muscle cells of the rat penis contain an extracellular isoform of superoxide dismutase (SOD), which converts superoxide radicals into hydrogen peroxide. 57 Cavernosal blood from men contains antioxidants vitamin C, albumin, bilirubin and uric acid. 62 In several diabetic animal models, decreased antioxidant levels, suggestive of oxidative stress, are measured in the penis, whereas antioxidant therapy leads to improved endothelial function and erectile ability. Vitamin E, sodium selenate, 63, 64 ascorbic acid, 65 alpha-lipoic acid and gamma-linolenic acid, 66 and melatonin 56, 58 restore neuronal and endothelial function in the corpus cavernosum. SOD and the metal chelator trientine also improve relaxation of diabetic corpus cavernosum. 67, 68 Overexpression of SOD in vivo by gene transfer to the diabetic rat penis reduces the increased superoxide anion levels and restores erectile function. 57 Moreover, FeTMPyP, a catalyst of peroxynitrite decomposition, which converts peroxynitrite to nitrate, partially corrects NOdependent diabetic autonomic neuropathy and vasculopathy in the corpus cavernosum from diabetic mice. 69 These studies demonstrate that oxidative stress has a major role in the development of ED associated with diabetes. NAD(P)H oxidases NAD(P)H oxidases are thought to be the major enzymes responsible for superoxide production in the vasculature in diseases such as diabetes, atherosclerosis and hypertension. NAD(P)H oxidase is an inducible electron transport system present in endothelial cells, smooth muscle cells, fibroblasts, and phagocytic mononuclear cells, and this enzyme generates superoxide through the assembly of a multisubunit protein complex utilizing NADH and NADPH as substrates. 70 Increased vascular superoxide production, decreased vascular NO production, increased NADPH oxidase activity and expression of the NADPH oxidase subunits p22 phox and gp91 phox homologue nox1 as well as p47 phox and p67 phox have been demonstrated in endothelial cells 71 and in blood vessels from diabetic animals 72, 73 and diabetic patients.
74
NAD(P)H oxidase is present in the corpus cavernosum from hypercholesterolemic rabbits 75 and in rabbit corpus cavernosal smooth muscle cells in response to thromboxane A2 mimetic. 76 However, the role of NAD(P)H oxidase in diabetes-associated ED has not been evaluated.
eNOS uncoupling
Uncoupled eNOS not only has decreased NOproducing functional activity (as discussed), but it also produces superoxide anion. It has been postulated that superoxide produced by NAD(P)H oxidase triggers eNOS uncoupling. 51 Recent in vivo data document that eNOS is an important superoxide source in vivo, contributing to endothelial dysfunction in diabetic animals and diabetic patients. 74 Increased formation of peroxynitrite, disruption of eNOS dimers, and reduced endothelium-dependent vasodilation has been demonstrated in the arteries of high-fat fed diabetic mice, 77 and in hearts of streptozotocin-treated LDLR knockout mice. 28 These data provide evidence that eNOS indeed may be a source of ROS in the vasculature.
Mitochondrial electron-transport chain
Hyperglycemia-induced overproduction of superoxide by the mitochondrial electron-transport chain triggers several pathways involved in the pathogenesis of diabetic complications. They include PKC activation and the shift of glucose metabolism from the glycolytic pathway to minor forms of glucose metabolism, such as aldose reductase, hexosamine and advanced glycation end products (AGEs) pathways. 78 Du et al. 6 recently defined activation of polyADP-ribose-polymerase and consequent decrease in glyceraldehyde-3 phosphate dehydrogenase activity as the downstream targets of increased ROS produced by the mitochondria, which diverts glucose into pathways of glucose overutilization.
Hyperglycemia-induced increase in polyol pathway has been demonstrated in the penis of diabetic animals. In streptozotocin-induced diabetic rats aldose reductase inhibitor, which inhibits the conversion of glucose to the sugar alcohol sorbitol, prevents a decline in NO-mediated endotheliumdependent and neurogenic vasorelaxation of the corpus cavernosum. 79 The importance of AGEs in diabetic ED was first described by Seftel et al. 80 AGEs impair both the neuronal and endothelial production of NO and cause cavernosal tissue and nerve fiber damage via membrane lipid peroxidation. 80, 81 AGEs accumulate in the collagen of the diabetic tunica and diabetic cavernosal tissue in men, in particular, endothelial and smooth muscle cells. [80] [81] [82] [83] [84] One of the receptors for AGEs, galectin-3, is also increased in the diabetic rat penis. 82 Inhibition of AGEs formation by aminoguanidine improves erectile response. [82] [83] [84] The diabetic human penis, but not serum, exhibits increases Endothelial dysfunction in diabetic ED B Musicki and AL Burnett in the AGE pentosidine, suggesting a tissue-specific effect of the AGEs. 80 HbA1c, an isoform of glycosylated hemoglobin, impairs endothelium-dependent relaxation of the rat corpus cavernosum, and this effect is reversed by SOD, implying a mediatory role of superoxide in HbA1c action. 85 These studies demonstrate that AGEs are important in the pathogenesis of diabetes-induced ED.
The role of PKC in diabetes-associated ED has been documented in several studies. Rat corpora cavernosa contain PKC a, b, g, e, d, Z, and i. 86 Corpus cavernosal vascular smooth muscle cells grown in a high glucose environment exhibit upregulated PKCb2 isoform with an associated increased ROS and decreased NO production, which may be reversed with vitamin E. 87 Inhibition of PKCbI and bII isoforms attenuates endothelial dysfunction in the corpus cavernosum of diabetic mice. 88 Thus, activation of PKC appears to be associated with endothelial dysfunction in the diabetic penis, although the mechanisms are not fully understood.
It has recently been shown that O-GlcNAc modification of eNOS prevents eNOS phosphorylation at Ser-1177 and enzyme's activation in the penis of diabetic rats, 18 as briefly discussed above.
NO-independent endothelium-derived relaxing factors
Endothelial cells release other vasodilators besides NO, including prostacyclin and endotheliumderived hyperpolarizing factor (EDHF). Impairment in their production/action contributes to endothelial dysfunction in diabetic ED. Prostacyclin, synthesized by both the endothelium and smooth muscle, is involved in cAMP-mediated smooth muscle relaxation. Peroxide may decrease the production of prostacyclin through tyrosine nitration of prostacyclin synthase. 89 This may not only eliminate the vasodilatory effects of prostacyclin, but also increase the release of the vasoconstrictors prostaglandin H 2 and thromboxane A 2 . Decreased prostacyclin production may contribute to endothelial dysfunction in the diabetic penis. In the corpus cavernosum of alloxan-induced diabetic rabbits 90 and streptozotocin-induced diabetic rats, 91 production of both NO and prostacyclin is decreased in parallel with decreased adenylyl cyclase activity. However, the exact role and mechanism of impaired prostacyclin production in diabetic ED is still not fully understood.
Endothelium-dependent vasodilation in smaller arteries and arterioles in a number of vascular beds is mostly attributed to non-NO/nonprostacyclininduced hyperpolarization mediated by EDHF. There is considerable controversy regarding the identity and the mechanism of action of EDHF, including whether it is a diffusible factor or reflects hyperpolarization transferred from the endothelium to the underlying smooth muscles via gap junctions. It is thought that the hyperpolarization of smooth muscle cell membrane by EDHF predominantly involves activation of calcium-dependent potassium channels. EDHF-mediated vasodilation in resistance vessels is impaired in a range of vascular beds in a number of animal models of type 1 and type 2 diabetes (reviewed in Bryan et al. 92 ). These findings suggest that alterations in EDHF activity in small resistance blood vessels may contribute significantly to microvascular complications associated with diabetes. Endothelial dysfunction in diabetic ED has been associated with defective EDHF-mediated vasodilation. Penile resistance arteries from diabetic patients with ED exhibit decreased EDHF-mediated endothelium-dependent relaxation compared to that of nondiabetic men with ED. 93 In diabetic rats enhancement of both EDHF and NO/3 0 , 5 0 -cyclic guanosine monophosphate (cGMP) pathways is necessary to reverse erectile dysfunction. 94 However, the mechanisms underlying impaired blood flow by EDHF in penile and nonpenile vascular beds in diabetes, as well as other disease states, remain to be fully elucidated.
RhoA/Rho-kinase contractile pathway
In addition to reduced vasodilation, the pathogenesis of diabetic ED is also associated with increased erectile tissue contractility. The RhoA/Rho-kinase pathway, which subserves a vasoconstrictor mechanism (evoked by norepinephrine through a-adrenergic receptors, endothelin-1, angiotensins and thromboxane A 2 ), is operative in the penis. [95] [96] [97] [98] This pathway is responsible for calcium-independent increase in vascular smooth muscle tone, known as calcium sensitization. RhoA-activated Rho-kinase (a and b isoforms) phosphorylates and inhibits regulatory myosin phosphatase target subunit 1 of myosin light chain phosphatase at Thr-696 and inhibits its activity, promoting smooth muscle contraction. 99 During erection this pathway is inhibited by NO. 100 In corporal smooth muscle cells NO activates soluble guanylyl cyclase by binding to its heme moiety, which results in increased levels of cGMP. Activation of cGMP-dependent protein kinase (protein kinase G) decreases intracellular calcium and antagonizes the RhoA/Rho-kinase pathway, causing NO-dependent relaxation of vascular smooth muscle cells in the corpora cavernosa. The inhibitory action of protein kinase G on RhoA/Rhokinase pathway possibly involves phosphorylation of RhoA at Ser-188, which prevents its translocation to the membrane and activation. 101 In addition, RhoA/ Rho-kinase suppresses eNOS gene expression and enzyme activity in the penis 13 and erectile
Endothelial dysfunction in diabetic ED B Musicki and AL Burnett function. 95, [102] [103] [104] In human umbilical vein endothelial cells the RhoA/Rho-kinase pathway inhibits Akt-dependent eNOS activity/phosphorylation at Ser-1177, 105 suggesting an additional means of interaction between eNOS-mediated relaxant and RhoA/Rho-kinase-mediated contractile pathways in the penis. Moreover, as shown in nonpenile vascular beds, ROS activate the RhoA/Rho-kinase pathway by promoting increased migration of RhoA to the plasma membrane and its activation, 106 thus stimulating vasoconstriction. Furthermore, Rhokinase stimulates NAD(P)H oxidase with consequent increase in the production of ROS, 107 further contributing to endothelial dysfunction.
In experimental diabetes, penile smooth muscle RhoA and Rho-kinase b expressions are increased, contributing to increased tissue contraction in response to endothelin. 108 The inhibition of RhoA expression in the penis of streptozotocin-induced diabetic rats by gene transfer of dominant negative RhoA increases eNOS protein content and restores erectile function. 13 These data suggest that upregulated Rho-kinase expression in the diabetic penis results in diminished endothelial NO production. These studies demonstrate that the RhoA/Rhokinase pathway contributes significantly to the pathogenesis of diabetes-associated ED.
Conclusion
Impairment of endothelial function is established as a major cause of diabetes-associated ED. Endothelial dysfunction results from impaired vasorelaxation, heightened vasoconstriction, increased production of free radicals, and actions of other mechanisms that promote endothelial injury. Figure 1 summarizes some of the discussed molecular pathways activated by hyperglycemia which lead to endothelial dysfunction. While many of these pathways are less well described in the penis than in the general vasculature, it is conceivable that they operate consistently in diseased vascular beds. Nonetheless, the exact mechanisms of endothelial dysfunction in the diabetic penis warrant further investigations. Strategies for restoring endothelial function in the diabetic penis may have important therapeutic implications for ED associated with diabetic, as well as nondiabetic vascular disease states.
Derangements in growth factors and cytokines such as VEGF, [109] [110] [111] basic fibroblast growth factor, 112 insulin-like growth factor-1 and its binding proteins, 113 and transforming growth factor-b 114 may induce endothelial dysfunction and ED in the setting of diabetes. Endocrine disorders such as low testosterone and changes in hormone receptors may also be associated with diabetes-associated ED. 10, [115] [116] [117] This broad and complex area of research is, however, beyond the scope of the present review. 
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